Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;20(4):693-712.
doi: 10.2174/1570159X19666210517150418.

Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)

Tommaso B Jannini  1 , Giorgio D Lorenzo  1   2 , Emanuela Bianciardi  1 , Cinzia Niolu  1 , Massimiliano Toscano  3   4 , Giacomo Ciocca  5 , Emmanuele A Jannini  1 , Alberto Siracusano  1
Affiliations
Review

Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)

Tommaso B Jannini et al. Curr Neuropharmacol. 2022.

Abstract

Psychiatric drugs have primacy for off-label prescribing. Among those, selective serotonin reuptake inhibitors (SSRIs) are highly versatile and, therefore, widely prescribed. Moreover, they are commonly considered as having a better safety profile compared to other antidepressants. Thus, when it comes to off-label prescribing, SSRIs rank among the top positions. In this review, we present the state of the art of off-label applications of selective serotonin reuptake inhibitors, ranging from migraine prophylaxis to SARS-CoV-2 antiviral properties. Research on SSRIs provided significant evidence in the treatment of premature ejaculation, both with the on-label dapoxetine 30 mg and the off-label paroxetine 20 mg. However, other than a serotoninergic syndrome, serious conditions like increased bleeding rates, hyponatremia, hepatoxicity, and post-SSRIs sexual dysfunctions, are consistently more prominent when using such compounds. These insidious side effects might be frequently underestimated during common clinical practice, especially by nonpsychiatrists. Thus, some points must be addressed when using SSRIs. Among these, a psychiatric evaluation before every administration that falls outside the regulatory agencies-approved guidelines has to be considered mandatory. For these reasons, we aim with the present article to identify the risks of inappropriate uses and to advocate the need to actively boost research encouraging future clinical trials on this topic.

Keywords: PSSD; SSRI; antidepressants; hypersexuality; off-label; paraphilic disorders; premature ejaculation.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Off-label uses of SSRIs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Radley D.C., Finkelstein S.N., Stafford R.S. Off-label prescribing among office-based physicians. Arch. Intern. Med. 2006;166(9):1021–1026. doi: 10.1001/archinte.166.9.1021. - DOI - PubMed
    1. Alexander G.C., Gallagher S.A., Mascola A., Moloney R.M., Stafford R.S. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol. Drug Saf. 2011;20(2):177–184. doi: 10.1002/pds.2082. - DOI - PMC - PubMed
    1. Eguale T., Buckeridge D.L., Winslade N.E., Benedetti A., Hanley J.A., Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch. Intern. Med. 2012;172(10):781–788. doi: 10.1001/archinternmed.2012.340. - DOI - PubMed
    1. Stafford R.S. Regulating off-label drug use--rethinking the role of the FDA. N. Engl. J. Med. 2008;358(14):1427–1429. doi: 10.1056/NEJMp0802107. - DOI - PubMed
    1. Faquih A.E., Memon R.I., Hafeez H., Zeshan M., Naveed S. A review of novel antidepressants: a guide for clinicians. Cureus. 2019;11(3):e4185. doi: 10.7759/cureus.4185. - DOI - PMC - PubMed

Substances

Grants and funding